Clinical Efficacy of Antianlotinib Combined with Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small-Cell Lung Cancer and Its Effect on Serum VEGF, CEA, and SCC-Ag

Table 4

Occurrence of adverse effects (AEs).

Types of AEs	Study group ( (%))		Control group ( (%))
	Levels 1–2	Levels 3–5	Levels 1–2	Levels 3–5
Gastrointestinal system
Nausea, vomit	12 (37.50)	2 (6.25)	8 (22.22)	0 (0.00)
Diarrhea	8 (25.00)	1 (3.13)	4 (11.11)	0 (0.00)
Oral mucositis	3 (9.38)	0 (0.00)	0 (0.00)	0 (0.00)
Respiratory system
Cough	4 (12.50)	0 (0.00)	2 (5.56)	0 (0.00)
Difficult breathing	3 (9.38)	0 (0.00)	4 (11.11)	0 (0.00)
Hemoptysis	2 (6.25)	0 (0.00)	2 (5.56)	0 (0.00)
Cardiovascular system
ECG QT prolongation	2 (6.25)	0 (0.00)	0 (0.00)	0 (0.00)
Sinus tachycardia	1 (3.13)	0 (0.00)	0 (0.00)	0 (0.00)
Immune-related AEs
Thyroid dysfunction	6 (18.75)	1 (3.13)	7 (19.44)	0 (0.00)
Pneumonia	4 (12.50)	0 (0.00)	3 (8.33)	1 (2.78)
Transfusion reaction	6 (18.75)	0 (0.00)	4 (11.11)	0 (0.00)
Colitis	1 (3.13)	0 (0.00)	1 (2.78)	0 (0.00)
Severe skin reaction	1 (3.13)	0 (0.00)	2 (5.56)	1 (2.78)

, compared with the control group.